Carlyle agrees to buy Johnson & Johnson unit for $4.15 bln

The Carlyle Group has agreed to acquire Johnson & Johnson's Ortho-Clinical Diagnostics business, which provides solutions for screening, diagnosing, monitoring and confirming diseases, for $4.15 billion. The transaction is subject to regulatory approvals and expected to close mid-2014. Equity for the deal is coming from Carlyle's sixth fund, which closed on $13 billion in November. The firm lined up financing for the deal from Barclays, Goldman Sachs, Credit Suisse, UBS and Nomura.

16 January 2014•3 mins read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles